Bauman, J. E., Licitra, L. F. L., Keam, B., Akhave, N., Yang, M., Harrington, K. J., Chung, C. H., Salas, S., Mirabile, A., Bauman, J. R., Saba, N. F., Wong, D. J., Tourneau, C. L., Muggeo, S., Jin, B., Cox, P., Braendle, E. E., Haddad, R. I. (2026). FIERCE-HN: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of ficlatuzumab (HGF/cMET mAb) in combination with cetuximab in participants with recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps6132